Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Trial of Atogepant for Preventive Treatment of Chronic Migraine in Pediatric Subjects 12–17 Years
2024-513836-28-00Phase 3Authorised
- Sponsor
- AbbVie Inc.
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial in chronic migraine comparing Atogepant with Placebo (2 arms). Primary endpoint: Change from Baseline in Mean Monthly Migraine Days Across the 12-Week Treatment Period. Planned start May 2025; status: authorised.
02
Drugs
atogepant
03
Conditions
chronic migraine
Beyond the preview
Go deeper on 2024-513836-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513836-28-00.